Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Magnetic resonance microscopy and correlative histopathology of the infarcted heart

  • Perez-Terol, Itziar
  • Rios-Navarro, César
  • de Dios, Elena
  • Morales, José Manuel|||0000-0002-4404-6735
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Perez-Sole, Nerea
  • Diaz, Ana
  • Minana, Gema
  • Segura-Sabater, Remedios
  • Bonanad, Clara
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Husser, Oliver
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Núñez, Julio|||0000-0003-1672-7119
  • Chorro, Francisco J.
  • Ruiz-Sauri, Amparo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Monleon, Daniel|||0000-0002-4803-1573
Delayed enhancement cardiovascular magnetic resonance (MR) is the gold-standard for non-invasive assessment after myocardial infarction (MI). MR microscopy (MRM) provides a level of detail comparable to the macro objective of light microscopy. We used MRM and correlative histopathology to identify infarct and remote tissue in contrast agent-free multi-sequence MRM in swine MI hearts. One control group (n = 3 swine) and two experimental MI groups were formed: 90 min of ischemia followed by 1 week (acute MI = 6 swine) or 1 month (chronic MI = 5 swine) reperfusion. Representative samples of each heart were analysed by contrast agent-free multi-sequence (T1-weighting, T2-weighting, T2*-weighting, T2-mapping, and T2*-mapping). MRM was performed in a 14-Tesla vertical axis imager (Bruker-AVANCE 600 system). Images from MRM and the corresponding histopathological stained samples revealed differences in signal intensities between infarct and remote areas in both MI groups (p-value < 0.001). The multivariable models allowed us to precisely classify regions of interest (acute MI: specificity 92% and sensitivity 80%; chronic MI: specificity 100% and sensitivity 98%). Probabilistic maps based on MRM images clearly delineated the infarcted regions. As a proof of concept, these results illustrate the potential of MRM with correlative histopathology as a platform for exploring novel contrast agent-free MR biomarkers after MI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Gonzalo
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Núñez, Eduardo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Chorro, Francisco J.
  • Cordero, Alberto|||0000-0003-0000-7109
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1 year readmission for HF in patients discharged for acute HF. We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and 1 year readmission for HF in patients discharged after acute HF. Participants' mean age was 73.4 ± 11.2 years, 50.8% were women, 44.7% had T2DM [including 527 (18.2%) on insulin therapy], and 52.7% had preserved ejection fraction. At 1 year follow-up, 518 (17.9%) patients had died and 693 (23.9%) were readmitted for HF. The crude risk of readmission for HF was higher in patients on insulin, with no differences in 1 year mortality. After multivariable adjustment, patients on insulin were at significantly higher risk of 1 year readmission for HF than patients with diabetes who were not on insulin (hazard ratio 1.28; 95% confidence interval 1.04-1.59, P = 0.022) and patients without diabetes (hazard ratio 1.26; 95% confidence interval 1.02-1.55, P = 0.035). Following acute HF, patients with T2DM on insulin therapy are at increased risk of readmission for HF. Further studies unravelling the mechanisms behind this association are warranted.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Núñez, Eduardo
  • Santas, Enrique
  • Valero, Ernesto
  • Lorenzo, Miguel|||0000-0001-9182-4459
  • Núñez, Gonzalo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Heredia, Raquel
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Chorro, Francisco J.
  • Núñez, Julio|||0000-0003-1672-7119
We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and NT-proBNP were measured during early hospitalization and evaluated as continuous and categorized in quartiles (Q). Negative binomial regressions were used to assess the association with the risk of recurrent AHF admission. The mean age of the sample patients was 76.7 ± 9.5 years and 1443 (60.9%) were women. Median values of CA125 and NT-proBNP were 38.3 (19.0-90.0) U/mL, and 2924 (1590-5447) pg/mL, respectively. During a median follow-up of 2.2 (0.8-4.6) years, 1200 (50.6%) patients died, and 2084 AHF admissions occurred in 1029 (43.4%) patients. After a multivariate adjustment, CA125, but not NT-proBNP, was positively and non-linearly associated with the risk of cumulative AHF-readmission (p < 0.001). Compared to Q1, patients belonging to Q2, Q3, and Q4 showed a stepwise risk increase (IRR = 1.29, 95% CI 1.08-1.55, p = 0.006; IRR = 1.35, 95% CI 1.12-1.63, p = 0.002; and IRR = 1.62, 95% CI 01.34-1.96, p < 0.001, respectively). In conclusion, CA125 predicted the risk of long-term AHF-readmission burden in patients with HFpEF and a recent admission for AHF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction, a pilot study

  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Ríos-Navarro, César
  • Núñez, Eduardo
  • Chorro, Francisco J.
  • López-Lereu, Maria Pilar
  • Monmeneu, Jose Vicente
  • Lupón, Josep|||0000-0002-5601-9611
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bodi, Vicente|||0000-0001-6425-5828
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40 patients with a first STEMI, LVEF < 50% and treated with primary percutaneous coronary intervention in which PCSK9 was measured 24 h postreperfusion. All patients underwent cardiac magnetic resonance imaging 1 week and 6 months after STEMI. Baseline characteristics were compared across median values of PCSK9. The association between PCSK9 levels and LVEF at 6 months was evaluated by analysis of covariance. The mean age of the sample was 60 ± 12 years and 33 (82.5%) were male patients. The infarct location was anterior in 27 patients (67.5%), and 9 patients (22.5%) were Killip class ≥ II. The mean 1 week and 6 month LVEF were 41 ± 7% and 48 ± 10%, respectively. The mean PCSK9 was 1.93 ± 0.38 U/mL. Testing the association between serum PCSK9 and 6 month LVEF with analysis of covariance revealed an inverse relationship (r = -0.35, P = 0.028). After multivariate adjustment, circulating PCSK9 remained significant and inversely associated with 6 month LVEF (P = 0.002). In patients with a first STEMI with reduced ejection fraction at index admission and treated with primary percutaneous coronary intervention, circulating PCSK9 was associated with lower LVEF at 6 months.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction, Looking Back to Move Forward. Focus on CMR

  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Marcos Garcés, Víctor|||0000-0001-5565-5547
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
  • Bodi, Vicente|||0000-0001-6425-5828
After a myocardial infarction (MI), despite the resolution of the coronary occlusion, the deterioration of myocardial perfusion persists in a considerable number of patients. This phenomenon is known as microvascular obstruction (MVO). Initially, the focus was placed on re-establishing blood flow in the epicardial artery. Then, the observation that MVO has profound negative structural and prognostic repercussions revived interest in microcirculation. In the near future, the availability of co-adjuvant therapies (beyond timely coronary reperfusion) aimed at preventing, minimizing, and repairing MVOs and finding convincing answers to questions regarding what, when, how, and where to administer these therapies will be of utmost importance. The objective of this work is to review the state-of-the-art concepts on pathophysiology, diagnostic methods, and structural and clinical implications of MVOs in patients with ST-segment elevation MIs. Based on this knowledge we discuss previously-tested and future opportunities for the prevention and repair of MVO.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction, A cardiovascular magnetic resonance study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Cediel, Germán|||0000-0001-9667-7507
  • Bär, Christian
  • Núñez, Julio|||0000-0003-1672-7119
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Ríos-Navarro, César
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bodi, Vicente|||0000-0001-6425-5828
  • Thum, Thomas|||0000-0003-4360-1511
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Reliable noninvasive prognostic biomarkers for left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) are needed. This study aimed to evaluate a panel of circulating microRNAs (miRNAs) as biomarkers of LV remodeling using cardiovascular magnetic resonance (CMR). We prospectively evaluated patients with a first STEMI treated with primary percutaneous coronary intervention who underwent CMR imaging at 1 week and 6 months after STEMI (n = 70). miRNAs were measured using PCR-based technologies in plasma samples collected at admission. The associations between miRNAs and LV diastolic and systolic volumes, and ejection fraction at 6-months were estimated in adjusted models. Median age was 60 years, 71.4% were male. miR-1254 was significantly associated in univariate analyses. Patients in the highest tertile of miR-1254 exhibited lower values of LVEDVI and LVESVI and higher values of LVEF at 1 week. After comprehensive multivariate adjustment including clinical, CMR variables, hs-troponin-T and NT-proBNP, miRNA-1254 was associated with decreasing LVESVI (P = 0.006), and borderline negative associated with LVEDVI (P = 0.063) at 6-months. miR-1254 also exhibited a significant positive association with increasing LVEF during follow-up (P < 0.001). Plasma miRNA-1254 predicted changes in LV volumes and LVEF at 6 months after STEMI. The value of miR-1254 to inform tailored treatment selection and monitor ongoing efficacy deserves further investigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion

  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Vidal, Veronica
  • Bonanad, Clara
  • Racugno, Paolo
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Miñana, Gema|||0000-0001-8777-2588
  • Husser, Oliver
  • Oltra, Ricardo
  • Núñez, Julio|||0000-0003-1672-7119
  • Chorro, Francisco J.
  • Bodi, Vicente|||0000-0001-6425-5828
  • Ruiz-Sauri, Amparo
We characterized the dynamics of eosinophils in blood and in the infarcted myocardium in patients and in a swine model of reperfused myocardial infarction (MI). The association of eosinophil dynamics with various outcomes was assessed. Serial eosinophil count and pre-discharge cardiac magnetic resonance were carried out in a prospective series of 620 patients with a first ST-elevation MI. In a swine model of reperfused MI, the dynamics of circulating eosinophils and their presence in the infarcted myocardium were determined. In autopsies from chronic MI patients, eosinophils were quantified. Patient eosinophil count sharply decreased 12h post-reperfusion compared to arrival. A lower minimum eosinophil count was associated with more extensive edema, microvascular obstruction, and infarct size as measured by cardiac magnetic resonance, and also with a higher rate of cardiac events (death, re-infarction, or heart failure) during follow-up. In the experimental model, eosinophil count boosted during ischemia and dropped back immediately post-reperfusion. Myocardial samples revealed progressive eosinophil migration into the infarcted myocardium, especially areas with microvascular obstruction. Markers of eosinophil maturation and survival (interleukin-5), degranulation (eosinophil cationic protein) and migration (eotoxin-1) were detected in the blood of patients, and in porcine myocardium. Eosinophil infiltration was detected in autopsies from chronic MI patients. Eosinopenia post-MI was associated with an impaired cardiac structure and adverse events. The decay in circulating eosinophils soon after reperfusion mirrors their migration into the infarcted myocardium, as reflected by their presence in heart samples from swine and patients. Further studies are needed to understanding this unexplored pathway and its therapeutic implications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Miñana, Gema|||0000-0001-8777-2588
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Sanchis, Juan|||0000-0003-0797-8709
  • Aimo, Alberto|||0000-0001-9129-9519
  • Emdin, Michele
  • Lupón, Josep|||0000-0002-5601-9611
  • Husser, Oliver
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively. The association between sNEP with either endpoint was evaluated across sex and BMI categories (≥ 25 kg/m 2 vs. < 25 kg/m 2). Bivariate count regression (Poisson) was used, and risk estimates were expressed as incidence rates ratio (IRR). During a median follow-up of 6.65 years (percentile 25%-percentile 75%:2.83-10.25), 702 (68.76%) patients died, and 406 (40%) had at least 1 HF hospitalization. Median values of sNEP and BMI were 0.64 ng/mL (0.39-1.22), and 26.9 kg/m 2 (24.3-30.4), respectively. Left ventricle ejection fraction was < 40% in 78.9% of patients, and 28% were women. In multivariable analysis, sNEP (main effect) was positively associated with HF hospitalizations (p = 0.001) but not with mortality (p = 0.241). The predictive value of sNEP for HF hospitalizations varied non-linearly across sex and BMI categories (p -value for interaction = 0.003), with significant and positive effect only on women with BMI ≥ 25 kg/m 2 (p = 0.039). For instance, compared to men, women with sNEP of 1.22 ng/mL (percentile 75%) showed a significantly increased risk (IRRs: 1.26; 95% CI: 1.05-1.53). The interaction analysis for mortality did not support a differential prognostic effect for sNEP (p = 0.072). In conclusion, higher sNEP levels in overweight women better predicted an increased risk of HF hospitalization.